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Attenuation of EGF receptor signaling by a metastasis
suppressor, the tetraspanin CD82/KAI-1
Elena Odintsova, Tsuyoshi Sugiura and Fedor Berditchevski 
The ‘metastasis suppressor’ CD82/KAI-1, a member of
the tetraspanin superfamily of transmembrane proteins,
is widely distributed in normal tissues [1], and has been
shown to be suppressed in the advanced stages of
various epithelial malignancies [2–6]. Although the
physiological relevance of this change is unknown, in
vitro data show that ectopically expressed CD82/KAI-1
can suppress tumor cell migration, a process underlying
the dissemination of tumor cells in vivo [5]. The function
of CD82/KAI-1 is not known and it has been proposed
that association of CD82/KAI-1 with other cell-surface
proteins may be pivotal in directing its biological
activities [7,8]. We show here that the CD82/KAI-1
tetraspanin is directly associated with the EGF receptor
(EGFR), and that ectopic expression of CD82/KAI-1 in
epithelial cells specifically suppresses EGF-induced
lamellipodial extensions and cell migration. In cells
expressing CD82/KAI-1, the initial activation of EGFR is
not affected, but subsequent desensitization of EGF-
induced signaling occurs more rapidly. This attenuation
is correlated with an increased rate of receptor
endocytosis. These results identify CD82/KAI-1 as a
new regulator of EGF-induced signaling and show that
the association of EGFR with the tetraspanin is critical
in EGFR desensitization.
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Results and discussion
In a search for cell-surface proteins with a functional link to
CD82/KAI-1, we found that anti-CD82 monoclonal anti-
bodies could co-immunoprecipitate EGFR from three dif-
ferent types of epithelial cells: small-cell lung carcinoma
(A549), primary keratinocytes and human mammary epithe-
lial cells (HB2/CD82) (Figure 1a). In the reciprocal experi-
ment using HB2/CD82 cells, we detected CD82/KAI-1 in
the EGFR immunoprecipitates as a characteristic smearing
33–38 kDa doublet (Figure 1b). The a3b1 integrin, a princi-
pal integrin partner of CD82/KAI-1 in epithelial cells [9],
was not found in the anti-EGFR immunoprecipitate pre-
pared from HB2/CD82 cells (Figure 1c), implying that the
CD82–EGFR and CD82–α3β1 complexes exist as sepa-
rate entities on the cell surface. Densitometric measure-
ments indicated that approximately 15–20% of the total
EGFR in HB2/CD82 cells could be co-immunoprecipi-
tated with CD82/KAI-1.
To establish the functional significance of the CD82–EGFR
association, we compared EGF-induced responses in a
newly developed pair of cell lines, HB2/zeo and
HB2/CD82. Derived from the HB2 cells, both lines were
selected as combined pools of drug-resistant colonies to
account for clonal variability. As assessed by flow cytome-
try, HB2/CD82 cells expressed CD82/KAI-1 at levels >
25-fold those in HB2/zeo cells. When motility responses
were analyzed in the wound closure assay, we found that
EGF-dependent migration of HB2/CD82 cells over 8
hours was decreased by more than 30% compared with
HB2/zeo cells (Figure 2a). In contrast, migration in
response to fetal calf serum (FCS) was similar for both
lines (Figure 2a). Using time-lapse video microscopy, we
found that early morphological responses to EGF were
also different. During the first 10 minutes after the EGF
Figure 1
CD82/KAI-1 is associated with EGFR in various epithelial cells.
(a) CD82/KAI-1 (CD82), EGFR and transferrin receptor (TFR)
complexes were immunoprecipitated (IP) from different sources as
indicated. Isotype-matched monoclonal antibody P3 was used as a
control (C). EGFR in the immunoprecipitates was detected by
immunoblotting. (b) The EGFR protein complex was
immunoprecipitated from HB2/CD82 cells. CD82/KAI-1 was detected
in the immunoprecipitate by immunoblotting. (c) CD82/KAI-1,
α3β1 and EGFR protein complexes were immunoprecipitated from
HB2/CD82 cells. The α3 integrin subunit was detected by
immunoblotting. See Supplementary material for methodological detail.
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stimulation, more than 80% of HB2/zeo cells began to
develop broad lamellipodial protrusions (Figure 2b, left
panel). In contrast, only 10–15% of HB2/CD82 cells dis-
played noticeable morphological changes in the presence
of EGF (Figure 2b, right panel).  Both HB2/zeo and
HB2/CD82 cells responded equally well when stimulated
with FCS (data not shown). Thus the EGF-induced
extensive lamellipodial formation in HB2/zeo, and the
attenuated response in HB2/CD82 cells, may explain the
differences in their motility in the wound closure assay. As
the extension of lamellipodial protrusions is accompanied
by reorganization of the actin cytoskeleton, we then ana-
lyzed distribution of actin filaments in HB2/zeo and
HB2/CD82 cells stimulated with the growth factors.
Immunofluorescence staining with TRITC-conjugated
phalloidin revealed that in HB2/zeo cells EGF induced
extensive polymerization of actin into filamentous struc-
tures in the cortical areas (Figure 2c, left panel). In the
EGF-treated HB2/CD82 cells, actin was organized into a
parallel array of filaments evenly distributed throughout
the cytoplasm (Figure 2c, right panel). The distribution of
polymerized actin in response to FCS was comparable in
both cell lines (Figure 2c, bottom panels). These results
indicated that in epithelial cells CD82/KAI-1 could selec-
tively modulate EGF-induced morphological responses
related to cellular motility.
EGF-induced activation of its receptor results in tyrosine
phosphorylation of EGFR itself and of a number of other
cellular proteins. Following phosphorylation, assembly of
various macromolecular protein complexes facilitates further
propagation of the signal [10]. Time-course analysis of
autophosphorylation of EGFR in HB2/CD82 cells showed
that after the initial robust phosphorylation of the receptor,
phosphorylation decreased at the later time points (Figure 3,
top panel). In contrast, changes in the phosphorylation level
of EGFR in HB2/zeo cells were insignificant (Figure 3, top
panel). Furthermore, the assembly of EGFR–Grb2 and
EGFR–Shc signaling complexes have followed the same
pattern (Figure 3, middle and bottom panels). Collectively,
these data show that ectopic expression of CD82/KAI-1 in
epithelial cells has a negative effect on EGF-induced sig-
naling. Furthermore, the attenuation of the signaling path-
ways leading to activation of Ras GTPase (through Grb2 or
Shc adaptor proteins) in the HB2/CD82 cells is consistent
with the observed decrease of cellular motility and suppres-
sion of the morphological responses to EGF.
Internalization and intracellular trafficking of the stimulated
EGF receptor are important for diversifying the intracellular
signals [11]. Dissociation of the endocytosed EGF–EGFR
complex in late endosomes and lysosomes leads to desensi-
tization of the receptor and attenuation of EGF-induced sig-
naling. To investigate whether rapid downregulation of
signaling in HB2/CD82 cells correlates with an increase in
the EGFR internalization rate, we compared the kinetics of
[125I]EGF uptake by HB2/zeo and HB2/CD82 cells. The
clearance rate of surface-bound [125I]EGF was significantly
higher in HB2/CD82 cells than in HB2/zeo cells
(Figure 4a): within the first 5 minutes, more than 85% of
[125I]EGF was internalized from the surface of HB2/CD82
cells compared with only 20% in HB2/zeo. The difference
was less dramatic after 10 minutes, and after 15 minutes
only negligible amounts of [125I]EGF were detected on the
surface of both HB2/CD82 and HB2/zeo cells (Figure 4a).
Second, we examined the removal of EGFR from the cell
surface after cells were treated with a saturated concentra-
tion of EGF. In the HB2/CD82 cells, only 30% of the
EGFR remained on the surface after treatment with EGF
for 5 minutes, whereas more than 80% was still present on
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Figure 2
Expression of CD82/KAI-1 in HB2 cells attenuates EGF-induced
morphological responses. (a) CD82/KAI-1 reduces EGF-induced cell
migration. A monolayer of serum-starved cells was wounded with a
pipet tip. Cell migration into the wound was recorded using a Hitachi
CCD camera connected to the computer. Images were processed
using the Image PC software package (Scion Co). The area of the
wound closed by cells over 8 h was calculated using a customized
WOUND module within the NIH image processing program. An
average of 3–5 experiments is shown. To standardize data obtained in
different experiments, a coefficient was introduced to equalize the
wound areas measured at time zero. Data are presented as a
difference between the wound areas at time zero and after 8 hours (in
square pixels). Error bars indicate the standard deviation of results
pooled from independent experiments. p < 0.02. (b) CD82/KAI-1
reduces EGF-induced formation of lamellipodia. Short-term
morphological responses of HB2/zeo cells (left panels) and
HB2/CD82 cells (right panels) to EGF. The phase-contrast images are
from a video sequence. Arrows point to lamellipodia in HB2/zeo and
HB2/CD82 cells. (c) Distribution of actin filaments in HB2/zeo and
HB2/CD82 cells stimulated with EGF and FCS for 15 min. The treated
cells were fixed with 2% paraformaldehyde and stained with TRITC-
conjugated phalloidin.
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the surface of HB2/zeo cells in the same conditions
(Figure 4b). The difference was even more dramatic after
60 minutes: ~50% of the initial amount of EGFR was
detected on the surface of HB2/zeo cells compared with
~8% on HB2/CD82 cells. In controls, we found that biotiny-
lated EGFR disappeared from the surface of untreated cells
at a comparable slow rate in both cell lines (data not shown).
These results show that expression of CD82/KAI-1 in
epithelial cells accelerated ligand-induced clearance of
EGFR from the cell surface. As the levels of EGFR in
HB2/zeo and HB2/CD82 cells exceed those of other
members of the ErbB family (E.O., unpublished results),
the majority of the internalized receptors are destined for
lysosomal degradation and inactivation of the receptor’s sig-
naling capacity. Consequently, the enhanced rate of endocy-
tosis can account for the rapid attenuation of EGF-induced
signaling in the HB2/CD82 cells. 
The EGF family of polypeptides are crucial to various
normal and pathological processes, including tissue differ-
entiation, wound healing and tumorigenesis. EGF-induced
signaling is controlled at various levels. These include the
ligand-induced dimerization of EGFR [12–14], membrane
compartmentalization of the activated receptor and its
substrates [15–17] and the intracellular routing of the
receptor and its degradation [18,19]. Although the molecu-
lar mechanisms of these processes are not fully under-
stood, they are each thought to involve distinct interactions
between ErbB receptors and other cellular proteins. Our
results identify CD82/KAI-1 tetraspanin as a new attenua-
tor of EGF-induced signaling, facilitating ligand-induced
endocytosis of the receptor and its subsequent desensiti-
zation. Consequently, the migratory response to EGF was
dramatically attenuated in cells expressing CD82/KAI-1.
These data provide further support for the idea that
ligand-induced endocytosis of surface receptors is an inte-
gral part of the signaling process that controls the ampli-
tude of cellular responses [20]. 
CD82/KAI-1 is associated with the EGFR membrane
complex, thus providing a first example of an accessory
transmembrane protein that regulates clearance of the
ligand-bound receptor from the cell surface. Interestingly,
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Figure 3
Expression of CD82/KAI-1 in HB2 cells changes the kinetics of
dephosphorylation of components of the EGF-dependent signaling
pathway. Serum-starved HB2/zeo and HB2/CD82 cells were treated
with EGF for the indicated times and the EGFR, Shc and Grb2 protein
complexes were precipitated. The levels of tyrosine phosphorylation
(pTyr) of the precipitated cellular proteins in treated and serum-starved
(–) cells was assessed by immunoblotting (WB).
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Figure 4
Effect of the expression of CD82/KAI-1 on ligand-dependent
internalization of EGFR. (a) Kinetics of internalization of [125I]EGF
(1 nM) pre-bound to the surface of HB2/zeo (light bars) and
HB2/CD82 (dark bars) cells. The data are presented as the
percentage of total EGF bound, calculated as ((total EGF bound/EGF
internalized) at time zero divided by (total EGF bound/EGF
internalized) at 5, 10 or 15 min) × 100. (b) The kinetics of ligand-
dependent removal of EGFR from the cell surface. HB2/zeo and
HB2/CD82 cells were treated with EGF (100 ng/ml) for the indicated
times. The amount of receptor remaining on the surface was assessed
by immunoprecipitation after cells were biotinylated at 4°C.
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the EGFR–CD82 complex is destabilized when EGF
binds to the receptor (see Supplementary material). This
observation not only distinguishes the EGFR–CD82
complex from other associations involving EGFR, but also
suggests that the tetraspanin may predetermine the signal-
ing potency of the receptor before its activation. 
Other members of the tetraspanin superfamily can form
complexes with a variety of surface transmembrane recep-
tors including integrins, CD4, CD8, CD19 and MHC class
II molecules [7,8], and it has been hypothesized that
tetraspanins modulate the receptors’ signaling activity
[7,8,21]. Our results show that tetraspanins may be involved
in the regulation of a particular step of the signaling process,
such as endocytosis of the activated receptor. This is an
important clue towards understanding the role of the
tetraspanins in signaling initiated by other receptors.
EGFR and CD82/KAI-1 are expressed together in a
variety of normal epithelia. Our results strongly suggest
that a change in the relative expression of these proteins
in epithelial tumors (for example, downregulation of
CD82/KAI-1 [2–6] or overexpression of EGFR) would
affect an important suppressive control on EGF-induced
signaling. The consequent sustained activation of EGFR
and protracted generation of proliferative and migratory
signals could enable the spread of the tumor and progres-
sion of the disease. 
Supplementary material
Supplementary material including additional methodological details and
figures showing the effects of EGF on the EGFR–CD82 complex and
the effects of CD82/KAI-1 on EGFR compartmentalization is available
at http://current-biology.com/supmat/supmatin.htm.
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